EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/115557
EW ASCRS PREVIEW 45 Cornea Day gears up for another year of dynamic presentations by Ellen Stodola EyeWorld Staff Writer 0.06% TRYPAN BLUE OPHTHALMIC SOLUTION TM VisionBlue is indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens.1 TM VisionBlue is intended to be applied directly on the anterior lens capsule, staining any portion of the capsule which comes in contact with the dye. It is recommended that after TM injection all excess VisionBlue be immediately removed from the eye by thorough irrigation of the anterior chamber. The dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non stained lens cortex and inner lens material.1 Terry Kim, M.D., co-chair of Cornea Day's Planning Committee, says the program continues to be a success. Source: EyeWorld C ornea Day attendees count on the lineup being up-to-date, informative, and useful, and planners say the 2013 event at the ASCRS•ASOA Symposium & Congress will continue that tradition. The program, scheduled for Friday, April 19, is designed to cater to both general ophthalmologists and cornea specialists. "Cornea Day continues to be a very successful program for us," said Terry Kim, M.D., professor of ophthalmology, Duke University Eye Center, Durham, N.C. Dr. Kim is one of the co-chairs for Cornea Day's Planning Committee from the ASCRS Cornea Clinical Committee, along with Donald T.H. Tan, M.D., president of the Cornea Society. Cornea Day is now averaging more than 1,500 attendees, and the continued on page 46 TM Rx Only Please see adjacent page for brief prescribing information. continued from page 44 survival, as well as the potentially detrimental effects of glaucoma surgery on graft survival. "New Invader in Corneal Graft Rejection: CMV Endotheliitis" by Jod S. Mehta, M.D., will address the differential diagnosis of graft rejection—that is, cases where apparent graft rejection is treated with steroids but it never improves. A final presentation titled "Against the Odds, the Success of Multiple Corneal Regrafts" by Kenneth M. Goins, M.D., will address declining success rates with successive grafts. "There are strategies to improve those success rates and then what do you do if you don't think the next graft is going to have much success, and the answer is usually a KPro," Dr. Rapuano said. EW EditorsÕ note: Dr. Rapuano has financial interests with Allergan. Contact information Rapuano: cjrapuano@willseye.org D.O.R.C. International B.V. Scheijdelveweg 2 3214 VN Zuidland The Netherlands Phone: +31 181 45 80 80 Fax: +31 181 45 80 90 E-mail: sales@dorc.nl VisionBlue is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL) is planned to be inserted into the eye because the dye may be absorbed by the IOL and stain the IOL. Adverse reactions reported following TM use of VisionBlue include inadvertent staining of the posterior lens capsule or vitreous face. Staining of the posterior lens capsule or vitreous face is generally self limited, lasting up to one week. ORDER INFORMATION TM VisionBlue is available in sterile packs of 10 syringes of 0.5ml/box Dutch Ophthalmic USA 10 Continental Drive Bldg 1, Exeter, NH 03833, U.S.A. Phone: or Call: (800) 75-DUTCH or (603) 778-6929 E-mail: sales@dutchophthalmicusa.com +1 800-75-DUTCH +1 603-778-6929 Fax: +1 603-778-0911 E-mail: sales@dutchophthalmicusa.com 1 Melles GJR, de Waard PWT, Pameyer JH, Houdijn Beekhuis W, Trypan blue capsule staining to visualize the capsulorhexis in cataract surgery. J Cataract Refractive Surgery 1999; 25:7-9